Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia

(2012) A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology.

Full text not available from this repository.

Official URL:


Rational In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms. However, the results are not consistent. Objective This study was designed to investigate the effect of modafinil added to risperidone in patients with chronic schizophrenia in a double blind and randomized clinical trial. Methods Participants were inpatients males (35) and females (11), ages 20-49 years at two teaching psychiatric hospital in Iran. All patients were in the active phase of the illness and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion 23 patients to risperidone 6 mg/day plus modafinil 200 mg/day and 23 patients to risperidone 6 mg/day plus placebo. The principal measure of outcome was the positive and negative syndrome scale (PANSS). Patients were assessed by a psychiatrist at baseline and after 2, 4, 6 and 8 weeks after the start of medication. Results The modafinil group had significantly greater improvement in the negative symptoms as well as PANSS total scores over the 8-week trial. Therapy with 200 mg/day of modafinil was well tolerated and no clinically important side effects were observed. Conclusion The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms. Nevertheless, results of larger-controlled trials are needed before recommendation for broad clinical application can be made. This trial is registered with the Iranian Clinical Trials Registry (IRCT138903131556N16). © 2011 Springer-Verlag.

Item Type: Article
Keywords: modafinil; placebo; risperidone, adult; article; clinical article; clinical assessment; combination chemotherapy; controlled study; diagnostic and statistical manual of mental disorders; dizziness; dose response; double blind procedure; drowsiness; drug dose increase; drug efficacy; drug tolerability; evening dosage; extrapyramidal symptom; female; headache; human; insomnia; male; multicenter study; nausea; outcome assessment; Positive and Negative Syndrome Scale; priority journal; prospective study; randomized controlled trial; response time; schizophrenia; sedation; sexual dysfunction; side effect; treatment duration; tremor; weight gain, Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hospitals, Psychiatric; Hospitals, Teaching; Humans; Iran; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Young Adult
Page Range: pp. 591-598
Journal or Publication Title: Psychopharmacology
Volume: 220
Number: 3
Identification Number: 10.1007/s00213-011-2513-z
ISSN: 00333158
Depositing User: مهندس جمال محمودپور

Actions (login required)

View Item View Item